MOLECULIN BIOTECH INC (MBRX) Stock Fundamental Analysis

NASDAQ:MBRX • US60855D4088

2.33 USD
-0.13 (-5.28%)
At close: Feb 23, 2026
2.39 USD
+0.06 (+2.58%)
Pre-Market: 2/24/2026, 5:24:19 AM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to MBRX. MBRX was compared to 521 industry peers in the Biotechnology industry. Both the profitability and financial health of MBRX have multiple concerns. MBRX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • In the past year MBRX has reported negative net income.
  • MBRX had a negative operating cash flow in the past year.
  • In the past 5 years MBRX always reported negative net income.
  • MBRX had a negative operating cash flow in each of the past 5 years.
MBRX Yearly Net Income VS EBIT VS OCF VS FCFMBRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M

1.2 Ratios

  • MBRX's Return On Assets of -203.20% is on the low side compared to the rest of the industry. MBRX is outperformed by 88.10% of its industry peers.
Industry RankSector Rank
ROA -203.2%
ROE N/A
ROIC N/A
ROA(3y)-85.68%
ROA(5y)-67.14%
ROE(3y)-177.93%
ROE(5y)-130.32%
ROIC(3y)N/A
ROIC(5y)N/A
MBRX Yearly ROA, ROE, ROICMBRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for MBRX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MBRX Yearly Profit, Operating, Gross MarginsMBRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

1

2. Health

2.1 Basic Checks

  • MBRX has more shares outstanding than it did 1 year ago.
  • MBRX has more shares outstanding than it did 5 years ago.
  • There is no outstanding debt for MBRX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
MBRX Yearly Shares OutstandingMBRX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20K 40K 60K 80K 100K
MBRX Yearly Total Debt VS Total AssetsMBRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

  • MBRX has an Altman-Z score of -18.96. This is a bad value and indicates that MBRX is not financially healthy and even has some risk of bankruptcy.
  • MBRX's Altman-Z score of -18.96 is on the low side compared to the rest of the industry. MBRX is outperformed by 81.96% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -18.96
ROIC/WACCN/A
WACCN/A
MBRX Yearly LT Debt VS Equity VS FCFMBRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M

2.3 Liquidity

  • MBRX has a Current Ratio of 1.39. This is a normal value and indicates that MBRX is financially healthy and should not expect problems in meeting its short term obligations.
  • With a Current ratio value of 1.39, MBRX is not doing good in the industry: 81.96% of the companies in the same industry are doing better.
  • A Quick Ratio of 1.39 indicates that MBRX should not have too much problems paying its short term obligations.
  • The Quick ratio of MBRX (1.39) is worse than 80.81% of its industry peers.
Industry RankSector Rank
Current Ratio 1.39
Quick Ratio 1.39
MBRX Yearly Current Assets VS Current LiabilitesMBRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 80.73% over the past year.
EPS 1Y (TTM)80.73%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%76.14%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • MBRX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 15.14% yearly.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y78.64%
EPS Next 2Y39.86%
EPS Next 3Y25.51%
EPS Next 5Y15.14%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
MBRX Yearly Revenue VS EstimatesMBRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2029 2030 2031 2032 2033 100M 200M 300M
MBRX Yearly EPS VS EstimatesMBRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -200 -400 -600 -800 -1K

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • MBRX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year MBRX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MBRX Price Earnings VS Forward Price EarningsMBRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MBRX Per share dataMBRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -10 -20 -30 -40 -50

4.3 Compensation for Growth

  • A more expensive valuation may be justified as MBRX's earnings are expected to grow with 25.51% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y39.86%
EPS Next 3Y25.51%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • MBRX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

MOLECULIN BIOTECH INC

NASDAQ:MBRX (2/23/2026, 8:00:00 PM)

Premarket: 2.39 +0.06 (+2.58%)

2.33

-0.13 (-5.28%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13
Earnings (Next)03-19
Inst Owners1.44%
Inst Owner Change-86.2%
Ins Owners2.1%
Ins Owner Change1.13%
Market Cap6.27M
Revenue(TTM)N/A
Net Income(TTM)-41.36M
Analysts82.22
Price Target24.82 (965.24%)
Short Float %16.19%
Short Ratio1.34
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-137.05%
Min EPS beat(2)-241.88%
Max EPS beat(2)-32.22%
EPS beat(4)1
Avg EPS beat(4)-56.12%
Min EPS beat(4)-241.88%
Max EPS beat(4)71.5%
EPS beat(8)3
Avg EPS beat(8)-27.86%
EPS beat(12)6
Avg EPS beat(12)-13.12%
EPS beat(16)8
Avg EPS beat(16)-7.08%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-52.29%
PT rev (3m)265%
EPS NQ rev (1m)21.31%
EPS NQ rev (3m)-3391.43%
EPS NY rev (1m)-3.54%
EPS NY rev (3m)-4175.69%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-55.82
EYN/A
EPS(NY)-7.65
Fwd EYN/A
FCF(TTM)-8.35
FCFYN/A
OCF(TTM)-8.35
OCFYN/A
SpS0
BVpS-10.01
TBVpS-14.15
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -203.2%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-85.68%
ROA(5y)-67.14%
ROE(3y)-177.93%
ROE(5y)-130.32%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.39
Quick Ratio 1.39
Altman-Z -18.96
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)53.16%
Cap/Depr(5y)71.82%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)80.73%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%76.14%
EPS Next Y78.64%
EPS Next 2Y39.86%
EPS Next 3Y25.51%
EPS Next 5Y15.14%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y16.27%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year6.33%
EBIT Next 3Y-6.25%
EBIT Next 5Y27.59%
FCF growth 1Y13.62%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y13.48%
OCF growth 3YN/A
OCF growth 5YN/A

MOLECULIN BIOTECH INC / MBRX FAQ

Can you provide the ChartMill fundamental rating for MOLECULIN BIOTECH INC?

ChartMill assigns a fundamental rating of 1 / 10 to MBRX.


What is the valuation status for MBRX stock?

ChartMill assigns a valuation rating of 1 / 10 to MOLECULIN BIOTECH INC (MBRX). This can be considered as Overvalued.


What is the profitability of MBRX stock?

MOLECULIN BIOTECH INC (MBRX) has a profitability rating of 0 / 10.


Can you provide the expected EPS growth for MBRX stock?

The Earnings per Share (EPS) of MOLECULIN BIOTECH INC (MBRX) is expected to grow by 78.64% in the next year.